BACKGROUND. Several lines of evidence suggest that male embryos may have greater vulnerability than female embryos to disordered inflammation; therefore, antiinflammatory drugs, such as low-dose aspirin (LDA), may alter the sex ratio. Here, we assessed the effect of LDA on male live birth and male offspring, incorporating pregnancy losses \( (n = 56) \) via genetic assessment, as part of a parallel-design, block-randomized, placebo-controlled trial of preconception LDA.

METHODS. Participants \( (615 \text{ treated with LDA, 613 treated with placebo}) \) ranged in age from 18 to 40 years of age, with 1 to 2 prior pregnancy losses. We estimated the intention-to-treat (ITT) risk ratio \( (RR) \) and 95% CI and assessed interaction with baseline high-sensitivity C-reactive protein (hsCRP) serum concentration — a marker of systemic inflammation.

RESULTS. Among the 1,078 women who completed follow-up \( (535 \text{ treated with LDA, 543 treated with placebo}) \), the male live birth ITT RR equaled 1.31 \( (95\% \text{ CI: 1.07–1.59}) \). With increasing tertile of hsCRP, the proportion of males at birth decreased in the placebo group, and the effect of LDA on male live birth increased \( (\text{first tertile: 48% male in LDA vs. 52% in placebo, ITT RR = 0.97, 95\% CI: [...]} \)
Sex ratio following preconception low-dose aspirin in women with prior pregnancy loss

Rose G. Radin,1 Sunni L. Mumford,1 Robert M. Silver,2 Laurie L. Lesher,3 Noya Galai,3 David Faraggi,3 Jean Wactawski-Wende,4 Janet M. Townsend,5 Anne M. Lynch,6 Hyagriv N. Simhan,7 Lindsey A. Sjaarda,1 Neil J. Perkins,1 Shvetha M. Zarek,1 Karen C. Schliep,1 and Enrique F. Schisterman1

1Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, Maryland, USA. 2Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, School of Medicine, Salt Lake City, Utah, USA. 3Department of Statistics, University of Haifa, Haifa, Israel. 4Department of Social and Preventive Medicine, University at Buffalo, Buffalo, New York, USA. 5Department of Family, Community and Rural Health, Commonwealth Medical College, Scranton, Pennsylvania, USA. 6Department of Obstetrics and Gynecology, University of Colorado at Denver, Aurora, Colorado, USA. 7Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Background. Several lines of evidence suggest that male embryos may have greater vulnerability than female embryos to disordered inflammation; therefore, antiinflammatory drugs, such as low-dose aspirin (LDA), may alter the sex ratio. Here, we assessed the effect of LDA on male live birth and male offspring, incorporating pregnancy losses (n = 56) via genetic assessment, as part of a parallel-design, block-randomized, placebo-controlled trial of preconception LDA.

Methods. Participants (615 treated with LDA, 613 treated with placebo) ranged in age from 18 to 40 years of age, with 1 to 2 prior pregnancy losses. We estimated the intention-to-treat (ITT) risk ratio (RR) and 95% CI and assessed interaction with baseline high-sensitivity C-reactive protein (hsCRP) serum concentration — a marker of systemic inflammation.

Results. Among the 1,078 women who completed follow-up (535 treated with LDA, 543 treated with placebo), the male live birth ITT RR equaled 1.31 (95% CI: 1.07–1.59). With increasing tertile of hsCRP, the proportion of males at birth decreased in the placebo group, and the effect of LDA on male live birth increased (first tertile: 48% male in LDA vs. 52% in placebo, ITT RR = 0.97 , 95% CI: 0.70–1.35; second tertile: 57% male in LDA vs. 43% in placebo, ITT RR = 1.36, 95% CI: 0.98–1.90; third tertile: 53% male in LDA vs. 35% in placebo, ITT RR = 1.70, 95% CI: 1.13–2.57; P interaction = 0.03). Analysis of pregnancy with male offspring yielded similar results.

Conclusion. Initiation of LDA prior to conception restored numbers of male live births and pregnancy with male offspring among women with 1 to 2 prior pregnancy losses. Moreover, our data suggest that LDA modulates inflammation that would otherwise reduce the conception or survival of male embryos.

Trial Registration. ClinicalTrials.gov NCT00467363.

Funding. Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.

Introduction

The ratio of male to female newborn infants has trended downward subtly but significantly over decades in North America (1, 2), Europe (3, 4), and Japan (5). More dramatic decreases in this ratio have been associated with parental exposure to environmental hazards, such as smoking (6), dioxin (7), methylmercury (8), and earthquakes (9, 10), suggesting that parental exposure to toxic chemicals and stress is particularly hazardous to male conception or survival. One potential pathway to altered sex ratios is maternal inflammation, which exhibits sex-dependent embryonic effects in bovines (11) and mice (12). In humans, a decidual proteotoxic stress response prevents implantation of nonviable embryos (13), and increased endometrial inflammation is associated with recurrent pregnancy loss (13, 14). Given the influence of inflammation on implantation, low-dose aspirin (LDA), an antiinflammatory drug, may improve implantation through reduction of inflammation. Indeed, some small trials noted that LDA increased the clinical pregnancy rate among women undergoing in vitro fertilization, although results were mixed (15–19). Recently, the Effects of Aspirin in Gestation and Reproduction (EAGeR) trial reported that preconception LDA treatment increased the probability of becoming pregnant, but did not prevent pregnancy loss, among women who were attempting pregnancy without fertility treatments and had a history of 1 pregnancy loss in the previous 12 months (20). LDA may also alter the sex ratio of pregnancies among women with a history of pregnancy loss, given the sex-dependent embryonic effects of maternal inflammation.
Table 1. Effect of LDA on the probability of male live birth among 1,086 women and mother-offspring pairs who completed follow-up (EAGeR trial, US, 2007–2012*)

<table>
<thead>
<tr>
<th></th>
<th>Among all participants (n = 1,086)</th>
<th>Among pregnancies (n = 783)</th>
<th>Among live births (n = 601)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>RR (95% CI)</td>
<td>RR (95% CI)</td>
</tr>
<tr>
<td>Overall</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>164</td>
<td>1.31 (1.07–1.59)</td>
<td>1.22 (1.01–1.48)</td>
</tr>
<tr>
<td>Placebo</td>
<td>128</td>
<td>1.00 (reference)</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>Stratified by tertile of preconception hsCRP at randomization</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tertile 1: 0.15–0.71 mg/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>49</td>
<td>0.97 (0.70–1.35)</td>
<td>0.93 (0.68–1.28)</td>
</tr>
<tr>
<td>Placebo</td>
<td>50</td>
<td>1.00 (reference)</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>Tertile 2: 0.72–2.08 mg/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>57</td>
<td>1.36 (0.98–1.90)</td>
<td>1.24 (0.91–1.70)</td>
</tr>
<tr>
<td>Placebo</td>
<td>45</td>
<td>1.00 (reference)</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>Tertile 3: 2.09–62.7 mg/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>48</td>
<td>1.70 (1.13–2.57)</td>
<td>1.64 (1.08–2.46)</td>
</tr>
<tr>
<td>Placebo</td>
<td>29</td>
<td>1.00 (reference)</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>Stratified by sex of previous live-born children</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nulliparous women</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>64</td>
<td>1.46 (1.04–2.04)</td>
<td>1.33 (0.96–1.83)</td>
</tr>
<tr>
<td>Placebo</td>
<td>46</td>
<td>1.00 (reference)</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>Parous women, no son</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>43</td>
<td>1.19 (0.81–1.74)</td>
<td>1.17 (0.81–1.68)</td>
</tr>
<tr>
<td>Placebo</td>
<td>31</td>
<td>1.00 (reference)</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>Parous women, with son</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>56</td>
<td>1.21 (0.88–1.66)</td>
<td>1.15 (0.86–1.55)</td>
</tr>
<tr>
<td>Placebo</td>
<td>51</td>
<td>1.00 (reference)</td>
<td>1.00 (reference)</td>
</tr>
</tbody>
</table>

*The unit of analysis was the participant and, in the case of pregnancy, the mother-offspring pair. Thus, 8 twin gestations each contributed two observations to the analysis, with accounting for correlated data using the generalized estimating equations of log-binomial regression. 1Pregnancies that were detected by urine hCG test. 2Number of live-born males. 3RD per 100 participants. 4RR and 95% CI were calculated out of pregnancies, with stabilized inverse probability weighting to adjust for the selection of pregnant participants. 5RD per 100 embryos and 95% CI were calculated out of embryos identified in pregnancies, with stabilized inverse probability weighting to adjust for the selection of pregnancies. 6RR and 95% CI were calculated out of live-born infants, with stabilized inverse probability weighting to adjust for the selection of pregnancies and live births. 7RD per 100 live-born infants and 95% CI were calculated out of live-born infants, with stabilized inverse probability weighting to adjust for the selection of pregnancies and live births. 8P values were calculated from the χ2 test of the regression coefficient for a cross-product term that modeled tertile of hsCRP and LDA assignment.

Among women with 1 to 2 prior losses, we evaluated the effect of daily preconception LDA treatment versus placebo on the secondary sex ratio, calculated as the proportion of males at birth, and on the sex ratio at implantation (males to females among human chorionic gonadotropin–detected pregnancies), by using genetic data that were collected systematically.

Results
The majority of the 1,228 women randomized to the LDA treatment group (615 women) and to the placebo group (613 women) had education beyond high school and an annual household income of ≥$75,000 (ref. 20 and Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI82357DS1). The LDA and placebo groups were on average very similar with respect to demographic characteristics and reproductive history, including race (mixed European descent 94% LDA vs. 96% placebo), employment status (employed, 73% LDA vs. 72% placebo), nulliparity (46% LDA vs. 47% placebo), and number of prior pregnancy losses (1 prior loss, 69% LDA vs. 66% placebo) (20).

Sex ratio at birth. Among the 1,078 women who completed the trial (535 in the LDA group, 543 in the placebo group), in the intention-to-treat (ITT) analysis, women assigned to LDA treatment were more likely to give birth to a live-born male than women assigned to the placebo (31% LDA vs. 23% placebo, risk ratio [RR] = 1.31, 95% CI: 1.07–1.59; risk difference [RD] per 100 women = 7.18, 95% CI: 1.92–12.4; Table 1). This was also true when the population was restricted to women who became pregnant (live-born males among pregnancies, 44% LDA vs. 37% placebo, RR = 1.22, 95% CI: 1.01–1.48) and to women who had a live birth (live-born male among participants with a live birth, 53% LDA vs. 44% placebo, RR = 1.24, 95% CI: 1.04–1.47). The probability of having a live-born female infant was similar in the LDA and placebo groups (among all participants who completed the trial, 24% LDA vs. 26% placebo, RR = 0.93, 95% CI: 0.76–1.12).

Sex ratio at implantation. In agreement with the analysis of male live births, LDA treatment increased the probability of pregnancy with male offspring among all participants (37% LDA vs. 28% placebo, RR = 1.30, 95% CI: 1.08–1.56; Table 2) and
among pregnancies (RR = 1.19, 95% CI: 1.01–1.41). In the simple quantitative bias analysis that evaluated bias from maternal cell contamination (MCC), the ITT RR for pregnancy with male offspring was 1.29 and the RD was 8.03 per 100 embryos, similar to the estimates from the primary analysis (RR = 1.30, RD = 8.52).

In the sensitivity analysis that imputed outcome data for pregnancy with male offspring among pregnancies that were detected by urine hCG test, the respective values were 48%, 57%, and 52%. Thus, the effect of LDA treatment on pregnancy incidence with male offspring was also stronger with increasing tertile of hsCRP first tertile: RR = 1.00, 95% CI: 0.74–1.34; second tertile: RR = 1.46, 95% CI: 1.04–2.04; third tertile: RR = 1.58, 95% CI: 1.07–2.33; P trend = 0.006) but not in the LDA group (RR = 0.99, 95% CI: 0.70–1.39, P trend = 0.66), after adjusting for maternal age, smoking, income, race, and marital status. LDA was not associated with female live births in any hsCRP tertile, and hsCRP was inversely associated with having a live-born male in pregnancy losses (Table 1).

The effect of LDA treatment on pregnancy incidence with male offspring was stronger with increasing tertile of hsCRP (first tertile: RR = 1.00, 95% CI: 0.74–1.34; second tertile: RR = 1.46, 95% CI: 1.07–2.00; third tertile: RR = 1.58, 95% CI: 1.07–2.33; P interaction = 0.03; Table 1). In the placebo group, the respective values were 48%, 57%, and 52%. Thus, hsCRP was inversely associated with having a live-born male in the placebo group (third tertile vs. first tertile, RR = 0.56, 95% CI: 0.38–0.84, P trend = 0.006) but not in the LDA group (RR = 0.99, 95% CI: 0.70–1.39, P trend = 0.66), after adjusting for maternal age, smoking, income, race, and marital status. LDA was not associated with female live births in any hsCRP tertile, and hsCRP was inversely associated with having a live-born male in any hsCRP tertile (P interaction = 0.03; Table 1). The effect of LDA treatment on pregnancy incidence with male offspring was also stronger with increasing tertile of hsCRP (first tertile: RR = 1.00, 95% CI: 0.74–1.34; second tertile: RR = 1.46, 95% CI: 1.07–2.00; third tertile: RR = 1.58, 95% CI: 1.07–2.33; P interaction = 0.03; Table 1).

The effect of LDA treatment on pregnancy incidence with male offspring was also stronger with increasing tertile of hsCRP (first tertile: RR = 1.00, 95% CI: 0.74–1.34; second tertile: RR = 1.46, 95% CI: 1.07–2.00; third tertile: RR = 1.58, 95% CI: 1.07–2.33; P interaction = 0.03; Table 1).

<table>
<thead>
<tr>
<th>Stratified by sex of previous live-born children</th>
<th>Among all women (n = 960)</th>
<th>Among pregnancies (n = 657)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>RR (95% CI)</td>
<td>RD (95% CI)</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Overall</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>175</td>
<td>1.30 (1.08–1.56)</td>
</tr>
<tr>
<td>Placebo</td>
<td>138</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>Stratified by tertile of preconception hsCRP at randomization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsCRP 0.15–0.71 mg/l</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>55</td>
<td>1.00 (0.74–1.34)</td>
</tr>
<tr>
<td>Placebo</td>
<td>56</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>hsCRP 0.72–2.05 mg/l</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>60</td>
<td>1.46 (1.07–2.00)</td>
</tr>
<tr>
<td>Placebo</td>
<td>47</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>hsCRP 2.06–62.7 mg/l</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDA</td>
<td>50</td>
<td>1.58 (1.07–2.33)</td>
</tr>
<tr>
<td>Placebo</td>
<td>31</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>P interaction^c</td>
<td>0.06</td>
<td>0.09</td>
</tr>
</tbody>
</table>
| Stratified by parity and previous son, the ITT RR of a live-born male was 1.46 (95% CI: 1.04–2.04) among nulliparous women, 1.19 (95% CI: 0.81–1.74) among parous women with no sons, and 1.21 (95% CI: 0.88–1.66) among parous women with ≥1 son (Table 1).
prior to conception restores the number of males to a conventional level, most likely by modulating inflammation. LDA was not associated with the overall risk of pregnancy loss or with offspring sex among pregnancy losses, suggesting that its actions to enhance the conception or survival of viable male embryos were complete soon after implantation. It is uncertain whether LDA had an effect before implantation, as spontaneous conceptions cannot be detected prior to this point.

In this population of women with 1 to 2 prior documented pregnancy losses, the low proportion of males at birth in the placebo group (44%) may be related to a disordered inflammatory milieu that is harmful for male conception or survival. This population is well-suited for studying this hypothesis, since the trial excluded women with diagnosed medical disorders, including polycystic ovarian syndrome, antiphospholipid syndrome, and others that reflect other causes of pregnancy loss (exclusion criteria were described previously, ref. 21). Because the proportion of males at birth was low only among women in the placebo group who had high levels of baseline inflammation, we suspect that inflammation may be hazardous to the conception or survival of male embryos. This is in agreement with in vivo animal studies (11, 12).

Emerging evidence suggests that maternal inflammation may have sexually dimorphic effects on preimplantation embryos.

### Discussion

Among women with 1 to 2 prior pregnancy losses, women who were randomized to daily LDA treatment while attempting pregnancy were more likely to have a live-born male, translating to an increased sex ratio at birth. We observed an interaction between LDA treatment and preconception hsCRP measured at randomization, a putative marker of the maternal inflammatory milieu. Higher maternal inflammation was associated with a reduced sex ratio among women taking placebo but not LDA, suggesting that LDA restored the number of male offspring in women with higher levels of inflammation. These effects were similar after restricting to pregnancies, demonstrating an effect operating on the embryos at risk, and after restricting to live births, demonstrating an effect estimate that followed the convention of the sex ratio literature (1, 2). Using genetic data from pregnancy losses, we found that there was a higher probability of having a pregnancy with male offspring—sex ratio at implantation—in the LDA group and that this association was not meaningfully biased by pregnancy losses with unknown offspring sex. The LDA and placebo groups were similar with respect to live-born females among all women randomized and males among the pregnancy losses.

Collectively, our results suggest that inflammation reduces conception or survival of male embryos and that LDA initiated prior to conception restores the number of males to a conventional level, most likely by modulating inflammation. LDA was not associated with the overall risk of pregnancy loss or with offspring sex among pregnancy losses, suggesting that its actions to enhance the conception or survival of viable male embryos were complete soon after implantation. It is uncertain whether LDA had an effect before implantation, as spontaneous conceptions cannot be detected prior to this point.

In this population of women with 1 to 2 prior documented pregnancy losses, the low proportion of males at birth in the placebo group (44%) may be related to a disordered inflammatory milieu that is harmful for male conception or survival. This population is well-suited for studying this hypothesis, since the trial excluded women with diagnosed medical disorders, including polycystic ovarian syndrome, antiphospholipid syndrome, and others that reflect other causes of pregnancy loss (exclusion criteria were described previously, ref. 21). Because the proportion of males at birth was low only among women in the placebo group who had high levels of baseline inflammation, we suspect that inflammation may be hazardous to the conception or survival of male embryos. This is in agreement with in vivo animal studies (11, 12).

Emerging evidence suggests that maternal inflammation may have sexually dimorphic effects on preimplantation embryos. Pre-
implantation embryos exhibit sexually dimorphic physiology (22, 23). In bovines, maternally derived colony-stimulating factor 2 cytokine decreased length and interferon-tau secretion of female embryos but increased length and interferon-tau secretion of male embryos (11). Colony-stimulating factor 2 also caused sex-dependent changes in the embryonic transcriptome and methylome (11), indicating that maternal inflammation may exert broader, sexually dimorphic effects. In mice, heat stress resulted in lower survival and higher hydrogen peroxide production among male pre-implantation embryos relative to those of female preimplantation embryos (12). This was explained by the lower expression by male embryos of the X-linked gene, glucose 6-phosphate dehydrogenase, which contributes to controlling free radicals (12).

LDA may have aided the implantation of viable male embryos by modulating inflammation in the decidua among individuals with a tendency toward overactive inflammation (14). Decidualized endometrial stromal cells respond to a poor-quality embryo with profound downregulation of the HSPA8 gene to induce a proteotoxic stress response (24). Embryonic metabolism may influence signaling, as poor-quality embryos are more active metabolically due to greater demands for cell repair (25, 26). The male embryo in particular may have elicited this over-active response due to its potentially greater metabolic activity (22, 23), thereby presenting more opportunity for “rescue” through LDA’s antiinflammatory actions compared with female embryos. As the science of maternal-fetal recognition is evolving, there is uncertainty around the precise biological mechanisms that may have produced our results.

The concept of a biological mechanism linked with both pregnancy loss and reduced sex ratio has some precedent in the literature. To our knowledge, there are two other broad categories of exposure that increase inflammation; these categories are associated both with increased risk of pregnancy loss and with reduced sex ratio at birth. While these mechanisms may not be acting in our study, their existence enhances the plausibility of an analogous mechanism that could have produced a reduced sex ratio among women with 1 to 2 prior pregnancy losses in the placebo group. First, maternal immunization against male-specific histocompatibility antigens (27) was hypothesized to explain a sex ratio of 0.76 among 213 births to Danish women following a diagnosis of unexplained secondary recurrent (≥3) pregnancy loss (27). This mechanism also increases inflammation. Second, parental exposure to certain environmental toxins — including lead (28), methylmercury (29), and high exposure to pesticides (30) — has been linked to both pregnancy loss and reduced sex ratio (31), which is a plausible mechanism for lower sex ratio among women with prior pregnancy loss, perhaps by inducing inflammation. In sum, prior studies have implicated inflammatory mechanisms in their findings of reduced sex ratio and pregnancy loss, and, by analogy, the lower sex ratio among women in the overall placebo group observed here can be regarded as potentially valid.

This study has several limitations to consider. It is possible — as it is in any study — that the differences observed were the result of a type I error. The observed sex ratio among the placebo group overall was lower than expected in the general population, while among the LDA group it was as expected. Thus, replication of our findings among a similar population with 1 to 2 prior pregnancy losses is needed to confirm our findings. Additionally, selection bias may have produced a reduced sex ratio among women in the placebo group if women who withdrew early from the placebo group were more likely to have a male live birth. This is unlikely since early withdrawal was fairly low and balanced between the groups (13% in the LDA group, 11% in the placebo group). Parental exposure to certain environmental toxins — including lead (28), methylmercury (29), and high exposure to pesticides (30) — has been linked to both pregnancy loss and reduced sex ratio (31), which is a plausible mechanism for lower sex ratio among women with prior pregnancy loss, perhaps by inducing inflammation. In sum, prior studies have implicated inflammatory mechanisms in their findings of reduced sex ratio and pregnancy loss, and, by analogy, the lower sex ratio among women in the overall placebo group observed here can be regarded as potentially valid.

This study has several limitations to consider. It is possible — as it is in any study — that the differences observed were the result of a type I error. The observed sex ratio among the placebo group overall was lower than expected in the general population, while among the LDA group it was as expected. Thus, replication of our findings among a similar population with 1 to 2 prior pregnancy losses is needed to confirm our findings. Additionally, selection bias may have produced a reduced sex ratio among women in the placebo group if women who withdrew early from the placebo group were more likely to have a male live birth. This is unlikely since early withdrawal was fairly low and balanced between the groups (13% in the LDA group, 11% in the placebo group). Parental exposure to certain environmental toxins — including lead (28), methylmercury (29), and high exposure to pesticides (30) — has been linked to both pregnancy loss and reduced sex ratio (31), which is a plausible mechanism for lower sex ratio among women with prior pregnancy loss, perhaps by inducing inflammation. In sum, prior studies have implicated inflammatory mechanisms in their findings of reduced sex ratio and pregnancy loss, and, by analogy, the lower sex ratio among women in the overall placebo group observed here can be regarded as potentially valid.

Table 4. Female live birth in relation to treatment assignment and hsCRP at randomization among 1,046 women and mother-offspring pairs (EAGeR trial, US, 2007–2012)

<table>
<thead>
<tr>
<th>hsCRP tertile</th>
<th>Placebo</th>
<th>LDA</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: 0.15–0.71 mg/l</td>
<td>53 0.91 (0.65–1.28)</td>
<td>47 1.12 (0.79–1.58)</td>
<td></td>
</tr>
<tr>
<td>2: 0.72–2.08 mg/l</td>
<td>53 1.00 (reference)</td>
<td>48 1.00 (reference)</td>
<td></td>
</tr>
<tr>
<td>3: 2.09–62.7 mg/l</td>
<td>59 1.00 (reference)</td>
<td>43 0.79 (0.56–1.10)</td>
<td></td>
</tr>
</tbody>
</table>

Stratified by tertile of hsCRP at randomization

hsCRP tertile 1: 0.15–0.71 mg/l
- Placebo: 46
- LDA: 52

hsCRP tertile 2: 0.72–2.08 mg/l
- Placebo: 43
- LDA: 47

hsCRP tertile 3: 2.09–62.7 mg/l
- Placebo: 59
- LDA: 52

Stratified by treatment assignment

LDA
- Placebo: 43
- LDA: 47

hsCRP tertile 1: 0.15–0.71 mg/l
- Placebo: 158
- LDA: 142

hsCRP tertile 2: 0.72–2.08 mg/l
- Placebo: 102
- LDA: 92

hsCRP tertile 3: 2.09–62.7 mg/l
- Placebo: 53
- LDA: 43

*This analysis included data from 1,039 participants who had hsCRP measured at randomization and completed follow-up. In the case of twin gestation, the embryo was the unit of analysis, with accounting for correlated data by using the generalized estimating equations extension of log-binomial regression. *Number of live-born females. *Model adjusted for maternal age, smoking, income, race, and marital status.
make little difference on an individual level, and LDA is not recommended for increasing the probability of having a son. We hope that our data will prompt further study of the relationships among inflammation, pregnancy loss, and sex ratio, ultimately leading to better reproductive outcomes.

Methods

The EAGeR trial was a block-randomized, double-blind, placebo-controlled, parallel-design trial of daily preconception 81 mg aspirin to prevent pregnancy loss (ClinicalTrials.gov NCT00467363) (21). It was conducted at 4 clinical sites in the US from 2007 to 2012 (Salt Lake City, Utah; Scranton, Pennsylvania; Denver, Colorado; and Buffalo, New York).

Participants were 18–40 years old; had regular menstrual cycles, 21 to 42 days in length; and were trying to conceive without fertility treatments. The original eligibility criteria specified 1 documented pregnancy loss that occurred at <20 weeks gestation in the previous 12 months and ≤1 live birth. Expanded eligibility criteria were implemented to increase enrollment, allowing women to enroll if they had 1 to 2 documented pregnancy losses at any time in the past that may have occurred before or after 20 weeks gestation and ≤2 live births.

Women were randomized in a 1:1 ratio to receive 81 mg aspirin daily or identical placebo (Figure 2). An automatic computer-generated randomization algorithm developed by the Data Coordinating Center used a permuted block design, with blocks of 6 or 8 in random order, defined by study center and eligibility criteria. At the randomization visit, which coincided with menstrual cycle days 2 to 4, participants provided a blood specimen, and preconception hsCRP serum concentration — a marker of systemic inflammation — was quantified using the Roche COBAS 6000 Chemistry Analyzer (Roche Diagnostics; limit of detection = 0.15 mg/l).

For up to 6 menstrual cycles, while attempting pregnancy, participants used study-provided fertility monitors (ClearBlue, Swiss Precision Diagnostics Gmbh) and urine hCG pregnancy tests (QuickVue, Quidel Corporation) at home and at end-cycle clinic visits. Those with a positive pregnancy test returned for an ultrasound at 6 to 7 weeks gestation to determine an ultrasound-confirmed pregnancy (clinical pregnancy). If there was no visible gestational sac, the participant was diagnosed with a peri-implantation loss and continued with prepregnancy follow-up for the remainder of the 6 cycles. Participants who became pregnant continued with monthly study visits throughout pregnancy and study medication through gestational week 36. Study completion occurred as planned in 2012.

Adverse effects are detailed in the Supplemental Methods.

Ascertainment of biological sex. The sex of live-born infants was ascertained by medical chart abstraction. In the event of a loss of a clinical pregnancy, products of conception were collected when possible for genetic testing. At the 6- to 7-week ultrasound visit, participants were asked to contact study staff as soon as possible if a pregnancy loss was diagnosed in a clinical setting and to collect a specimen with study-issued equipment if a pregnancy loss occurred at home. When possible, an immediate attempt was made to assess fetal or placental
karyotype or chromosomal microarray. Specimens were refrigerated for up to 24 hours and then frozen at −80°C, with some additional frozen specimens subjected to chromosomal microarray. Genetic testing was performed on 84 of 127 clinical pregnancy losses (including 2 twin gestations): 55 tests determined sex and 29 tests had no results due to testing failure (n = 5) or indeterminate result (n = 24). One 15-week phenotypic male had no genetic analysis.

Statistics. The ideal method to estimate an effect of LDA on embryonic survival that operates differentially by sex would assess the association with male offspring at various stages of the reproductive process. Our data analysis aimed to approximate this ideal, given the constraints on feasibility, by including the sex of pregnancy losses determined by genetic testing, when available, and by conducting a sensitivity analysis that imputed outcome data for pregnancy losses with no determination of offspring sex.

The primary analysis used an ITT approach, comparing male live births among participants with complete follow-up in treatment and placebo groups by calculating the RR, RD, and corresponding 95% CI. The purpose was to estimate the effect of LDA on carrying and giving birth to a live-born male among all women offered treatment. We also estimated the effect of LDA on female live births to clarify whether it was male or female survival that produced a change in the sex ratio. Because the ITT analysis included women who did not become pregnant, we conducted secondary analyses that were restricted to pregnancies detected by urine hCG testing and to live births. As restrictions to pregnancies and live births might break the randomization, we adjusted for the selection through the use of stabilized inverse probability weights (32) in a weighted log-binomial regression model with robust variance estimation. The unit of analysis was the woman and, in the case of pregnancy, the offspring. Thus, 8 twin gestations contributed 2 observations each, and we estimated the RR and RD with robust standard errors by using PROC GENMOD in SAS version 9.4 (SAS Institute). For all statistical tests, a P value from the χ² test of the coefficient of one cross-product variable that modeled treatment assignment and sex was considered significant.

The analysis that evaluated the relation of LDA with having a pregnancy with male offspring (sex ratio at implantation) assessed the effect of LDA on a pregnancy with a male embryo that implanted and was detected by a urine hCG test, whether or not it survived to live birth. An ITT analysis as well as a secondary analysis that restricted to pregnancies counted women as having the event of interest if they had either a live-born male or a pregnancy loss with male sex determined. The unit of analysis was the woman and, in the case of pregnancy, the offspring. Thus, 8 twin gestations contributed 2 observations each, and we estimated the RR and RD with robust standard errors by using PROC GENMOD in SAS version 9.4 (SAS Institute). For all statistical tests, a P value of less than 0.05 was considered significant.

Sensitivity analyses. Female karyotypes of first-trimester losses may be inaccurate due to MCC (33), and 15 of 17 euploid female karyotype results did not exclude possible MCC. A simple quantitative bias analysis (34) that was informed by an external validation study (33) evaluated bias from outcome misclassification to the estimated effect of LDA on pregnancy with male offspring.

Furthermore, the analysis of pregnancy with male offspring excluded 126 offspring with undetermined sex (55 peri-implantation losses and 71 clinical pregnancy losses). To assess potential bias from missing data, we first imputed the offspring sex of these pregnancy losses under every possible scenario of the percentage male of missing data (0%–100%) in each treatment group. Then, for each scenario, we calculated the P value from the χ² test of the association of LDA and male offspring if the sex was determined in all pregnancies (Figure 1). We restricted our discussion to results from data sets that met our assumptions for plausible values of percentage male in the treatment and placebo groups (44%–56%, the central triangular area of Figure 1): (a) the percentage male out of missing data in each treatment group could vary from the observed value among pregnancies in the placebo group to the observed value among pregnancies in the treatment group; and (b) the percentage male of missing data in the treatment group was greater than or equal to that of the placebo group. The median gestational age of these pregnancy losses was 8 weeks (interquartile range: 7–10 weeks, range: 2–20 weeks). Our range of plausible values for percentage male is compatible with the finding that a majority of pregnancy losses are female during the period from implantation through the first half of the second trimester (35). The observed values for percentage of male and female pregnancy losses were corrected for outcome misclassification due to MCC (33).

Stratified analyses. To further test whether LDA may affect sex ratio by modulating inflammation, we stratified analyses by preconception hsCRP serum concentration. Participants with hsCRP concentration measured (n = 1,039) were categorized according to tertiles of preconception serum hsCRP (first tertile: 0.15–0.71 mg/l; second tertile: 0.72–2.08 mg/l; third tertile: 2.09–62.7 mg/l). The presence of statistical interaction was tested with the Wald χ² test of the coefficient of one cross-product variable that modeled treatment assignment and hsCRP tertile median. Furthermore, we estimated the RR and 95% CI of male live birth in the highest-versus-lowest tertile of preconception hsCRP among women assigned to placebo and among women assigned to LDA and calculated the P value for linear trend in each group by using the Wald χ² test of the coefficient of a linear variable for hsCRP tertile median. Finally, we stratified the analysis of LDA and male live birth by previous live-born children (nulliparous, parous with no sons, parous with ≥1 son) in order to assess whether LDA may affect the sex ratio by modulating an aberrant maternal immune response to H-Y antigens (27).

The study size for this clinical trial was based on the enrollment goal of 1,600 participants in order to detect a 10% absolute difference in the EAGeR trial’s primary endpoint, live birth rate, with 80% power and a 5% type I error rate. The sample-size calculation assumed a live birth rate of 40% over 6 cycles in the placebo arm and loss to follow-up of 20%. However, actual performance was better than the assumptions, with live birth rate of 53% in the placebo arm and loss to follow-up of 12%.

Study approval. The study protocol was approved by the Intermountain Healthcare Institutional Review Board (Salt Lake City, Utah, USA), The Wright Center for Graduate Medical Education Institutional Review Board (Scranton, Pennsylvania, USA), the University at Buffalo Health Sciences Institutional Review Board (Buffalo, New York, USA), and the Colorado Multiple Institutional Review Board (Aurora, Colorado, USA). Participants provided written informed consent prior to study enrollment.

Acknowledgments This research was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland (contract nos. HHSN267200603423, HHSN267200603424, and HHSN267200603426). The study funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The content of this article is solely the responsibility of.

Stratified analyses. To further test whether LDA may affect sex ratio by modulating inflammation, we stratified analyses by preconception hsCRP serum concentration. Participants with hsCRP concentration measured (n = 1,039) were categorized according to tertiles of preconception serum hsCRP (first tertile: 0.15–0.71 mg/l; second tertile: 0.72–2.08 mg/l; third tertile: 2.09–62.7 mg/l). The presence of statistical interaction was tested with the Wald χ² test of the coefficient of one cross-product variable that modeled treatment assignment and hsCRP tertile median. Furthermore, we estimated the RR and 95% CI of male live birth in the highest-versus-lowest tertile of preconception hsCRP among women assigned to placebo and among women assigned to LDA and calculated the P value for linear trend in each group by using the Wald χ² test of the coefficient of a linear variable for hsCRP tertile median. Finally, we stratified the analysis of LDA and male live birth by previous live-born children (nulliparous, parous with no sons, parous with ≥1 son) in order to assess whether LDA may affect the sex ratio by modulating an aberrant maternal immune response to H-Y antigens (27).

The study size for this clinical trial was based on the enrollment goal of 1,600 participants in order to detect a 10% absolute difference in the EAGeR trial’s primary endpoint, live birth rate, with 80% power and a 5% type I error rate. The sample-size calculation assumed a live birth rate of 40% over 6 cycles in the placebo arm and loss to follow-up of 20%. However, actual performance was better than the assumptions, with live birth rate of 53% in the placebo arm and loss to follow-up of 12%.

Study approval. The study protocol was approved by the Intermountain Healthcare Institutional Review Board (Salt Lake City, Utah, USA), The Wright Center for Graduate Medical Education Institutional Review Board (Scranton, Pennsylvania, USA), the University at Buffalo Health Sciences Institutional Review Board (Buffalo, New York, USA), and the Colorado Multiple Institutional Review Board (Aurora, Colorado, USA). Participants provided written informed consent prior to study enrollment.

Acknowledgments This research was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland (contract nos. HHSN267200603423, HHSN267200603424, and HHSN267200603426). The study funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The content of this article is solely the responsibility of.

The Journal of Clinical Investigation

The Journal of Clinical Investigation
the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the NIH. The authors thank Emily Mitchell for advice on data analysis and Allen Wilcox and anonymous reviewers for valuable comments on the paper.

Address correspondence to: Enrique F. Schisterman, Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6100 Executive Boulevard, Rockville, Maryland 20854 USA. Phone: 301.435.6893; E-mail: schistee@mail.nih.gov.